VIDEO: Indications for AI screening system expanded in Europe
Click Here to Manage Email Alerts
Key takeaways:
- EyeArt is cleared in the U.S. for diabetic retinopathy detection.
- In the European Union, the system is also cleared for detection of age-related macular degeneration and glaucomatous optic nerve damage.
NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Kaushal Solanki discusses the EyeArt AI eye screening system, which was cleared by the FDA for diabetic retinopathy detection in 2020.
Solanki spoke about the recent European Union medical device regulation clearance for the system for the detection of age-related macular degeneration and glaucomatous optic nerve damage, in addition to diabetic retinopathy.
“Now, our customers in Europe can help many more patients who are at risk of diabetic retinopathy but also at risk of AMD and glaucoma ... and give them a very comprehensive report that includes three conditions rather than one,” he said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts